Alvotech Awaits Date With Destiny, With FDA Inspection To Begin On 6 March
Icelandic Firm’s Reykjavik Facility Must Pass FDA Inspection To Unlock Biosimilars
As Alvotech reported its first annual financial results, the company spoke of the imminent FDA inspection at its Icelandic manufacturing facility. An earlier inspection has so far put the kibosh on US approval for Alvotech’s proposed Humira (adalimumab) biosimilar.
